MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32170
Abstract: An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET… read more here.
Keywords: cetuximab; hnscc; resistance cetuximab; activation ... See more keywords
A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-020-01604-5
Abstract: Current evidence indicates that resistance to the tyrosine kinase-type cell surface receptor (HER2)-targeted therapies is frequently associated with HER3 and active signaling via HER2-HER3 dimers, particularly in the context of breast cancer. Thus, understanding the… read more here.
Keywords: sorla; response; her2; resistance ... See more keywords
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-0504
Abstract: We explored potential associations of the PD-1/PD-L1/PD-L2 pathway with clinical characteristics, outcome, and expression of EGFR, HER2, HER3 in oropharyngeal squamous cell carcinoma (OPSCC) using an institutional database. Protein expression was assessed by IHC on… read more here.
Keywords: egfr her2; her2 her3; expression;
Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-gs6-04
Abstract: Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast cancers. The HER2 tyrosine kinase inhibitor (TKI) neratinib has shown clinical activity against cancers harboring HER2 activating mutations. Co-occurring HER2 and HER3… read more here.
Keywords: breast cancer; her2 her3; her2;
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps2615
Abstract: TPS2615Background: Next generation sequencing of solid tumors will increasingly reveal mutations in cancer genes, including EGFR, HER2 and HER3 mutations. Afatinib is a small molecule, which select... read more here.
Keywords: egfr her2; her2 her3; oncology; oncology explorative ... See more keywords
Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.65
Abstract: 65Background: HER2 status is a predictive biomarker to response to trastuzumab in metastatic gastric adenocarcinomas. However, relatively little is known about the role of HER2 and HER3 in the non-metastatic disease in European population. Methods:… read more here.
Keywords: her2; her3 status; expression; her2 her3 ... See more keywords
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2019.30.e75
Abstract: Objectives Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of… read more here.
Keywords: her2; overexpression her2; ovarian cancer; her2 her3 ... See more keywords